AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update

Author's Avatar
Aug 09, 2022

AVROBIO%2C+Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.